Predictions
Argo Blockchain plc
Start price
Target price
Perf. (%)
€3.02
07.03.21
07.03.21
-
07.03.22
07.03.22
-76.49%
08.03.22
08.03.22
EBIT growth >5% per year expected
Capable Management
Growths faster than the competition
Marathon Digital Holdings
Start price
Target price
Perf. (%)
€25.01
07.03.21
07.03.21
€40.00
07.03.22
07.03.22
-20.82%
08.03.22
08.03.22
Growths faster than the competition
Medium risks for its business
McPhy Energy S.A.
Start price
Target price
Perf. (%)
€27.40
07.03.21
07.03.21
€32.00
07.03.22
07.03.22
-41.93%
08.03.22
08.03.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Fair valuation
Top Rating
Computer Programs + Sys
Start price
Target price
Perf. (%)
€25.80
07.03.21
07.03.21
-
07.03.22
07.03.22
18.60%
08.03.22
08.03.22
Risky Investment
Ur-Energy Inc.
Start price
Target price
Perf. (%)
€0.88
07.03.21
07.03.21
€3.00
07.03.22
07.03.22
78.61%
08.03.22
08.03.22
Market Leader or Top 3
Very Future proof/growth oriented business model
Bed Bath & Beyond Inc.
Start price
Target price
Perf. (%)
€28.67
07.03.22
07.03.22
€21.00
07.03.23
07.03.23
-33.73%
07.03.22
07.03.22
Capable Management
Good culture
Could be worthwhile Investment >10% per year
Little innovation
Evofem Biosciences Inc.
Start price
Target price
Perf. (%)
€6.20
21.02.22
21.02.22
€13.50
21.02.23
21.02.23
2.90%
07.03.22
07.03.22
Could be very worthwhile Investment >20% year
ION Geophysical Corp.
Start price
Target price
Perf. (%)
€0.48
25.02.22
25.02.22
€1.00
25.02.23
25.02.23
156.28%
07.03.22
07.03.22
Could be very worthwhile Investment >20% year
Arcimoto Inc
Start price
Target price
Perf. (%)
€6.22
02.03.22
02.03.22
€12.00
02.03.23
02.03.23
-4.82%
07.03.22
07.03.22
Could be very worthwhile Investment >20% year
Innate Pharma
Start price
Target price
Perf. (%)
€4.80
05.09.21
05.09.21
-
05.09.22
05.09.22
-47.79%
07.03.22
07.03.22
Probably not worthwhile Investment
HighPoint Resources Corp.
Start price
Target price
Perf. (%)
€7.96
06.03.21
06.03.21
-
06.03.22
06.03.22
-41.52%
07.03.22
07.03.22
Could be worthwhile Investment >10% per year
Altamira Therapeutics Ltd.
Start price
Target price
Perf. (%)
€2.60
06.03.21
06.03.21
-
06.03.22
06.03.22
-73.65%
07.03.22
07.03.22
Could be very worthwhile Investment >20% year
2G Energy AG
Start price
Target price
Perf. (%)
€103.40
02.03.22
02.03.22
€110.00
02.03.23
02.03.23
-8.03%
05.03.22
05.03.22
Top 10 in its market
Revenue growth >5% per year expected
Sustainability is very important
Significant cyclical dependencies
Molecular Templates Inc.
Start price
Target price
Perf. (%)
€2.31
20.02.22
20.02.22
-
20.02.23
20.02.23
-6.49%
05.03.22
05.03.22
Risky Investment
Myovant Sciences Ltd
Start price
Target price
Perf. (%)
€11.05
20.02.22
20.02.22
-
20.02.23
20.02.23
-1.99%
05.03.22
05.03.22
Could be very worthwhile Investment >20% year
Fate Therapeutics Inc.
Start price
Target price
Perf. (%)
€29.39
20.02.22
20.02.22
-
20.02.23
20.02.23
-0.65%
05.03.22
05.03.22
Could be very worthwhile Investment >20% year
Aurora Cannabis Inc.
Start price
Target price
Perf. (%)
€3.70
20.02.22
20.02.22
-
20.02.23
20.02.23
-18.09%
05.03.22
05.03.22
Could be very worthwhile Investment >20% year
ProQR Therapeutics N.V.
Start price
Target price
Perf. (%)
€1.03
22.02.22
22.02.22
€1.00
22.02.23
22.02.23
-25.24%
05.03.22
05.03.22
Could be worthwhile Investment >10% per year
Capable Management
Bad culture
Wasgau Produktions & Handels AG
Start price
Target price
Perf. (%)
€14.60
19.02.22
19.02.22
-
19.02.23
19.02.23
-2.05%
05.03.22
05.03.22
Top 10 in its market
Future proof or reliable business model
Could be very worthwhile Investment >20% year
Rising EBIT margin expected
BayWa AG VNA
Start price
Target price
Perf. (%)
€36.90
19.02.22
19.02.22
-
19.02.23
19.02.23
-2.44%
05.03.22
05.03.22
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Aixtron SE
Start price
Target price
Perf. (%)
€18.10
03.03.21
03.03.21
-
03.03.22
03.03.22
2.79%
04.03.22
04.03.22
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation